Stay updated with breaking news from Bedema. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
THR-687 is a potent pan-RGD integrin antagonist holding potential as a next generation first line therapy for DME, currently a $4.5 billion market opportunity THR-687 also holds promise for treatment
Fatigue 17 3 12 2 Lipase increased 17 3 17 2 Anaemia 16 5 2 - Amylase increased 15 1 13 1 Nausea 12 1 7 - Vomiting 12 3 4 - Oedema peripheral 11 - 9 - Abdominal pain 10 2 1 -... | October 7, 2021
LONDON, Oct. 7, 2021 /PRNewswire/ -- The Al Hikma Modern Hospital, Zarqa, Jordan, today announced it is the first hospital in the region to adopt the geko device to treat and prevent acute lower
Therapeutic agents for pain relief in appropriate doses and the introduction of new drugs are a few of the factors fueling the growth of this market. JERSEY CITY, N.J., Oct. 7, 2021 /PRNewswire/
Decision taken to move the highest dose of THR-149 (0.13mg) into Part B of the study based on favorable safety profile and positive efficacy data Oxurion is moving into Part B of study evaluating THR-149